The relationship between markers of extracellular cardiac matrix turnover: Infarct healing and left ventricular remodelling following primary PCI in patients with first-time STEMI

European Heart Journal

Volumn 35, Issue 6, 2014, Pages 395-402

  Manhenke, Cord ^a,b   Ueland, Thor ^c   Jugdutt, Bodh I ^d   Godang, Kristin ^c   Aukrust, Pål ^c   Dickstein, Kenneth ^a,b   Ørn, Stein ^a  

^a STAVANGER UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

^d UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Collagen turnover; Extracellular cardiac matrix; Remodelling; STEMI

Indexed keywords

COLLAGEN TURNOVER; EXTRACELLULAR CARDIAC MATRIX; REMODELLING; STEMI;

ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; COLLAGEN TYPE I; EXTRACELLULAR MATRIX; FEMALE; HUMANS; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; MATRIX METALLOPROTEINASES; MIDDLE AGED; MYOCARDIAL INFARCTION; PEPTIDE FRAGMENTS; PERCUTANEOUS CORONARY INTERVENTION; POSTOPERATIVE CARE; PROCOLLAGEN; TISSUE INHIBITOR OF METALLOPROTEINASES; VENTRICULAR REMODELING;

EID: 84894236771     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/eht482     Document Type: Article

References (34)

1. Jugdutt BI. Ventricular remodeling after infarction and the extracellular collagen matrix: when is enough enough? Circulation 2003;108:1395-1403.
2. Souders CA, Bowers SLK, Baudino TA. Cardiac fibroblast: the renaissance cell. Circ Res 2009;105:1164-1176.
3. Spinale FG. Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. Physiol Rev 2007;87:1285-1342.
4. Lopez B, Gonzalez A, Querejeta R, Larman M, Diez J. Alterations in the pattern of collagen deposition maycontribute to the deterioration of systolic functionin hypertensive patients with heart failure. J Am Coll Cardiol 2006;48:89-96.
5. Laviades C, VaroN, Fernandez J, Mayor G, Gil MJ, Monreal I, Diez J. Abnormalities of the extracellular degradation of collagen type I in essential hypertension. Circulation 1998;98:535-540.
6. Lopez B, Gonzalez A, Varo N, Laviades C, Querejeta R, Diez J. Biochemical assessment of myocardial fibrosis in hypertensive heart disease. Hypertension 2001;38: 1222-1226.
7. Diez J, Panizo A, Gil MJ, Monreal I, Hernandez M, Pardo Mindan J. Serum markers of collagen type I metabolism in spontaneously hypertensive rats: relation to myocardial fibrosis. Circulation 1996;93:1026-1032.
8. Cerisano G, Parodi G, Dovellini EV, Migliorini A, Tommasi M, Raspanti S, Buonamici P, Taddeucci E, Valenti R, Antoniucci D. Time course of serum collagen types I and III metabolism products after reperfused acute myocardial infarction in patients with and without systemic hypertension. J Hum Hypertens 2009;23:40-47.
9. Webb CS, Bonnema DD, Ahmed SH, Leonardi AH, McClure CD, Clark LL, Stroud RE, Corn WC, Finklea L, Zile MR, Spinale FG. Specific temporal profile of matrix metalloproteinase release occurs in patients after myocardial infarction: relation to left ventricular remodeling. Circulation 2006;114:1020-1027.
10. Robinson TF, Cohen-Gould L, Factor SM, Eghbali M, Blumenfeld OO. Structure and function of connective tissue in cardiac muscle: collagen types I and III in endomysial struts and pericellular fibers. Scanning Microsc 1988;2:1005-1015.
11. Lopez B, Gonzalez A, Diez J. Circulating biomarkers of collagen metabolism in cardiac diseases. Circulation 2010;121:1645-1654.
12. Risteli J, Niemi S, Trivedi P, Maentausta O, Mowat AP, Risteli L. Rapid equilibrium radioimmunoassay for the amino-terminal propeptide of human type III procollagen. Clin Chem 1988;34:715-718.
13. Kelly D, Squire IB, Khan SQ, Dhillon O, Narayan H, NgKH, Quinn P, Davies JE, NgLL. Usefulness of plasma tissue inhibitors of metalloproteinases as markers of prognosis after acute myocardial infarction. Am J Cardiol 2010;106:477-482.
14. Kelly D, Khan SQ, Thompson M, Cockerill G, Ng LL, Samani N, Squire IB. Plasma tissue inhibitor of metalloproteinase-1 and matrix metalloproteinase-9: novel indicators of left ventricular remodelling and prognosis after acute myocardial infarction. Eur Heart J 2008;29:2116-2124.
15. Cavusoglu E, Ruwende C, Chopra V, Yanamadala S, Eng C, Clark LT, Pinsky DJ, Marmur JD. Tissue inhibitor of metalloproteinase-1 (TIMP-1) is an independent predictor of all-cause mortality, cardiac mortality, and myocardial infarction. Am Heart J 2006;151:1101. e1-8.
16. Manhenke C, Orn S, Squire I, Radauceanu A, Alla F, Zannad F, Dickstein K. The prognostic value of circulating markers of collagen turnover after acute myocardial infarction. Int J Cardiol 2011;150:277-282.
17. Iraqi W, Rossignol P, Angioi M, Fay R, Nuee J, Ketelslegers JM, Vincent J, Pitt B, Zannad F. Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) Study. Circulation 2009;119:2471-2479.
18. Orn S, Manhenke C, Greve OJ, Larsen AI, Bonarjee VVS, Edvardsen T, Dickstein K. Microvascular obstruction is a major determinant of infarct healing and subsequent left ventricular remodelling following primary percutaneous coronary intervention. Eur Heart J 2009;30:1978-1985.
19. Kelly D, Khan S, Cockerill G, Ng LL, Thompson M, Samani NJ, Squire IB. Circulating stromelysin-1 (MMP-3): a novel predictor of LV dysfunction, remodelling and allcause mortality after acute myocardial infarction. Eur J Heart Fail 2008;10:133-139.
20. Orn S, Manhenke C, Squire IB,NgL, Anand I, Dickstein K. Plasma MMP-2,MMP-9 and N-BNP in long-termsurvivors following complicated myocardial infarction: relation to cardiac magnetic resonance imaging measures of left ventricular structure and function. J Card Fail 2007;13:843-849.
21. Lottenburger T, Junker P, Horslev-Petersen K. Diurnal variation of connective tissue metabolites in early and long-standing rheumatoid arthritis and in healthy individuals. Scand J Rheumatol 2011;40:88-94.
22. WolthersOD,Heuck C,Heickendorff L.Diurnal variations inserumandurinemarkers of type I and type III collagen turnover in children. Clin Chem 2001;47:1721-1722.
23. Steg PG, James SK, Atar D, Badano LP, Blomstrom-Lundqvist C, Borger MA, Di Mario C, Dickstein K, Ducrocq G, Fernandez-Aviles F, Gershlick AH, Giannuzzi P, Halvorsen S, Huber K, Juni P, Kastrati A, Knuuti J, Lenzen MJ, Mahaffey KW, Valgimigli M, van 't Hof A, Widimsky P, Zahger D. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012;33:2569-2619.
24. Cleutjens JP, Verluyten MJ, Smiths JF,Daemen MJ. Collagen remodeling after myocardial infarction in the rat heart. Am J Pathol 1995;147:325-338.
25. McCormick RJ, Musch TI, Bergman BC, Thomas DP. Regional differences in LV collagen accumulation and mature cross-linking after myocardial infarction in rats. Am J Physiol 1994;266(1 Pt 2):H354-H359.
26. Barasch E, Gottdiener JS, Aurigemma G, KitzmanDW, Han J, Kop WJ, Tracy RP. The relationship between serum markers of collagen turnover and cardiovascular outcome in the elderly/clinical perspective. Circ Heart Fail 2011;4:733-739.
27. Fang L,Gao X-M, Samuel CS, SuY, Lim YL, DartAM,Du X-J. Higher levels of collagen and facilitated healing protect against ventricular rupture following myocardial infarction. Clin Sci 2008;115:99-106.
28. Manhenke C, Orn S, von Haehling S,Wollert KC, Ueland T, Aukrust P, Voors AA, Squire I, Zannad F, Anker SD, Dickstein K. Clustering of 37 circulating biomarkers by exploratory factor analysis in patients following complicated acute myocardial infarction. Int J Cardiol 2013;166:729-735.
29. Zannad F, Dousset B, Alla F. Treatment of congestive heart failure: interfering the aldosterone-cardiac extracellular matrix relationship. Hypertension 2001;38: 1227-1232.
30. Uusimaa P, Risteli J, Niemela M, Lumme J, Ikaheimo M, Jounela A, Peuhkurinen K. Collagen scar formation after acute myocardial infarction: relationships to infarct size, left ventricular function, and coronary artery patency. Circulation 1997;96: 2565-2572.
31. Zannad F, Alla F, Dousset B, Perez A, Pitt B. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators. Circulation 2000;102:2700-2706.
32. Poulsen SH, Host NB, Jensen SE, Egstrup K. Relationship between serum aminoterminal propeptide of type III procollagen and changes of left ventricular function after acute myocardial infarction. Circulation 2000;101:1527-1532.
33. Tian H, Cimini M, Fedak PWM, Altamentova S, Fazel S, Huang M-L, Weisel RD, Li R-K. TIMP-3 deficiency accelerates cardiac remodeling after myocardial infarction. J Mol Cell Cardiol 2007;43:733-743.
34. Spinale FG, Escobar GP, Hendrick JW, Clark LL, Camens SS, Mingoia JP, Squires CG, Stroud RE, Ikonomidis JS. Chronic matrix metalloproteinase inhibition following myocardial infarction in mice: differential effects on short and long-term survival. J Pharmacol Exp Ther 2006;318:966-973.